FOLH1 and Thrombocytopenia: Specifically (Hofman et al., 2024), the most common grade 3–4 adverse events in the Lu-PSMA and CAB groups were neutropenia (33% vs. 53%), thrombocytopenia, anemia, diarrhea, and fatigue.